Tricky, just to bring you up to speed on “Silly”. Before Behzad’s slate of proposed directors actually became directors, he agreed to have a conference call with up to 15 contributors to this board. I selected 15 people and we go the chance to talk to him and ask questions so that each of us could more knowledgeably make a decision on what slate of directors to vote for.
One of the questions was what he thought the value of 132 was or could be. Of course he hedged and said that he hasn’t been in a position to look deeply into everything 132, that he could only speculate based on what the company had released. He said that if 132 gained approval for TNBC it would have significant value, if a second indication, like UT, were approved, that would boost the value. If it worked its way up towards front line in multiple indications, the number would get “Silly”, in other words, a stock price he wouldn’t even speculate on at that point as it WOULD sound silly.
I think most of us see “silly” as triple digits, but we don’t see it as unlikely. The lack of execution on AA set us back in the dream of “silly”, but the company has forged ahead in the mentioned milestones towards getting to “silly” in doing trials in multiple indications and gained collaborations with other companies to investigate 132 with other treatments, Parp inhibitors and PDL-1’s. So the path has been set and journey started, doing exactly what he said it would take to get to Silly. That’s the destination. There are plenty of stops along the way that are great places to get of in part or in whole. Some need Silly to make a read difference in their later years, but many here have accumulated enough that the Silly destination isn’t really necessary for a great retirement. I think we have a great shot at getting there, but I plan to cast off a little as different stops along the way since I’ve been foolishly concentrated in a single stock for quite a while.
So no, Silly isn’t behind us, it’s quite a ways off in the distance. |
